Vaccination

Valneva Receives Notice of European Commission’s Intent to Terminate COVID-19 Vaccine Purchase Agreement

Retrieved on: 
Monday, May 16, 2022 - 6:15am
CpG, Royal commission, Severe acute respiratory syndrome coronavirus 2, Company, Saint-Herblain, European Commission, Nasdaq, European Medicines Agency, Webcast, Health, Infection, Vaccine, Emergency Use Authorization, Vero, COVID-19, Ministry, Health care, EC, APA, Vaccination, United Kingdom, Committee for Medicinal Products for Human Use, National Health Regulatory Authority, CHMP, EMA, United Arab Emirates, Technology, Lyme disease, Chikungunya, 1018, Medication, Committee, European Directive on Traditional Herbal Medicinal Products, Medical device, VLA2001

Saint-Herblain (France), May 16, 2022 Valneva SE , a specialty vaccine company, today announced that it has received a notice from the European Commission (EC) of intent to terminate the advance purchase agreement (APA) for Valnevas inactivated whole-virus COVID-19 vaccine candidate VLA2001.

Key Points: 
  • Saint-Herblain (France), May 16, 2022 Valneva SE , a specialty vaccine company, today announced that it has received a notice from the European Commission (EC) of intent to terminate the advance purchase agreement (APA) for Valnevas inactivated whole-virus COVID-19 vaccine candidate VLA2001.
  • Thomas Lingelbach, Chief Executive Officer of Valneva, commented, the EC decision is regrettable especially as we continue to receive messages from Europeans who are looking for a more traditional vaccine solution.
  • Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need.
  • The Company takes a highly specialized and targeted approach to vaccine development and then applies its deep understanding of vaccine science to develop prophylactic vaccines addressing these diseases.

Valneva Receives Emergency Use Authorization from the United Arab Emirates for its Inactivated COVID-19 Vaccine

Retrieved on: 
Monday, May 16, 2022 - 6:00am
CpG, Bahraini, Severe acute respiratory syndrome coronavirus 2, VLA2001, Company, Nasdaq, Conditional, NHRA, Infection, Vaccine, Vero, COVID-19, VLA, Trust, Vaccination, EMA, United Arab Emirates, Technology, Euronext Paris, Lyme disease, Chikungunya, 1018, Health, Emirates

Saint Herblain (France), May 16, 2022 Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the United Arab Emirates (UAE) granted emergency use authorization for Valnevas inactivated, adjuvanted COVID-19 vaccine, VLA2001.

Key Points: 
  • Saint Herblain (France), May 16, 2022 Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the United Arab Emirates (UAE) granted emergency use authorization for Valnevas inactivated, adjuvanted COVID-19 vaccine, VLA2001.
  • As the only dual-adjuvanted, whole-virus inactivated COVID-19 vaccine approved by the UAE Ministry of Health and Prevention, VLA2001 could offer an alternative vaccine solution to people across the Emirates.
  • This authorization follows Conditional Marketing Authorization from the UK MHRA1, which was granted last month, and emergency use authorization from the Bahraini NHRA in March 20222.
  • VLA2001 is currently the only whole virus, inactivated, adjuvanted COVID-19 vaccine in clinical development in Europe.

Family Sues After Michigan Girl, 17, Denied Kidney Transplant for Refusing Shots

Retrieved on: 
Friday, May 13, 2022 - 11:55pm
Hospital, House at 1514 N. Michigan Street, Patient, Patriot, Parent, Dialysis, Adult, COVID-19, Vaccination, Kidney, Patti Grace Smith, Patti Smith, Transplant, Douglas v. U.S. District Court ex rel Talk America, Jenna, Children's Hospital, WTP, LLC, District court, GLOBE, Dentistry, Campau family

Alisa Campau has end-stage renal disease and only minimal functioning in her one remaining kidney.

Key Points: 
  • Alisa Campau has end-stage renal disease and only minimal functioning in her one remaining kidney.
  • that no person may ever be denied life-saving medical treatment just for refusing a shot."
  • As Jenna explains, it is critical that Alisa be placed on the pediatric transplant list before she turns 18 this July.
  • Pediatric transplant patients receive high priority, so Alisa could receive a kidney within months."

AACOM Strongly Recommends Hybrid Residency Interviews for 2022-23 Cycle

Retrieved on: 
Friday, May 13, 2022 - 4:49pm
Physician, Program, National Resident Matching Program, Risk, Osteopathy, Student, Medicine, UIM, Overalls, Bias, American Association of Colleges of Osteopathic Medicine, Journal, Environment, Goal, Health, Association, AACOM, Interview, Research, Vaccination, NRMP, National Medical Association, DO, UIMS, Plague, Hospital, Safety, Travel, Faculty, National Exit Test, American Association, DOS, COVID, Osteopathic medicine in the United States, MD, CEO, GLOBE, Health insurance

Bethesda, MD, May 13, 2022 (GLOBE NEWSWIRE) -- The American Association of Colleges of Osteopathic Medicine (AACOM) strongly recommends that residency programs give students, from every background and medical school, the option to interview in person or virtually during the 2022-23 application cycle.

Key Points: 
  • Bethesda, MD, May 13, 2022 (GLOBE NEWSWIRE) -- The American Association of Colleges of Osteopathic Medicine (AACOM) strongly recommends that residency programs give students, from every background and medical school, the option to interview in person or virtually during the 2022-23 application cycle.
  • In the spirit of meeting both these goals, today AACOM calls on all residency programs to offer both in-person and virtual interviews and allow students to choose which option best fits their needs.
  • AACOM supported the recommendations that all interviews move online during this period, with the caveat that further research and study must be done before any future recommendations were made to limit or eliminate in-person interviews.
  • We therefore strongly recommend that all residency programs offer both in-person and virtual interviews for the 2022-23 application cycle.

Global $13.8 Bn Bioplastics Market Forecast to 2028 - Increasing Focus on Innovations and Technological Advancements - ResearchAndMarkets.com

Retrieved on: 
Friday, May 13, 2022 - 2:13pm
Chemicals, Plastics, Manufacturing, Toray Industries, Mitsubishi Chemical Corporation, KPMG, Plant, Agriculture, Bacteria, GDP, Artnet, FDI, COVID-19, Asia-Pacific Research and Training Network on Trade, Vaccination, NatureWorks, Industry, CAGR, Construction, BASF, Growth, Bioplastic, Pharmaceutical industry, Renewable energy, Saudia

The "Bioplastics Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type and Application" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Bioplastics Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type and Application" report has been added to ResearchAndMarkets.com's offering.
  • Based on type, the global bioplastics market is segmented into biodegradable and non-biodegradable.
  • Also, the market for the same segment is expected to grow at a faster rate during the forecast period.
  • The growth of various end-use industries in Asia Pacific is driving the growth of the bioplastics market.

RINO Carlos Gimenez (FL-26) Continues to Vote with Nancy Pelosi and the Radical Democrats in Congress: Wasteful $40 Billion U.S. Taxpayer Funded Handout to Ukraine

Retrieved on: 
Friday, May 13, 2022 - 12:59pm
Firearm, Congressional caucus, Republican, Ethics, Constitution, Policy, Citizenship, Legislation, Vaccination, Corruption, Federation, RINO, United States congressional committee, Congress, Social democracy, Communist China, Amnesty, Database, Online gambling, Drug, Internet service provider, Whaling

WASHINGTON, May 13, 2022 /PRNewswire/ -- RINO Carlos Gimenez (FL-26th Congressional District) continues to vote with Nancy Pelosi and the radical Democrats in Congress.

Key Points: 
  • WASHINGTON, May 13, 2022 /PRNewswire/ -- RINO Carlos Gimenez (FL-26th Congressional District) continues to vote with Nancy Pelosi and the radical Democrats in Congress.
  • RINO Gimenez voted for the wasteful $40 Billion Taxpayer funded handout to Ukraine, while millions of U.S. Citizens are homeless and starving on the streets.
  • RINO Gimenezotherwise known as a Socialist Democrat, has a long record of supporting radical socialist policy, dating back to his time as Miami-Dade Mayor.
  • In Washington, D.C., RINO Gimenez has voted with Nancy Pelosi and the radical leftists.

Badger Infrastructure Solutions Ltd. Announces 2022 First Quarter Results

Retrieved on: 
Friday, May 13, 2022 - 1:54am
Sewage, Company, Soil, Natural gas, EBITDA, Depreciation, Loosen' Control, Telecommunication, Electricity, Webcast, SEDAR, Tax, Health, COVID-19, Marketing, Adjustment, Legislation, Consolidated, Vaccination, TSX, Retirement, Weather, Red deer, Time, Lists of disasters, RPT, Communication, Safety, Solution, Sale, IFRS, Growth, Water, Business, Risk management, Sales, Renewable energy, Environmental remediation, Audit, Bookkeeping, Vaccine, Retail, Bank, Omicron, Badger

For year over year comparison purposes, the 2022 dividends payable is $4.6 million as at March 31, 2022.

Key Points: 
  • For year over year comparison purposes, the 2022 dividends payable is $4.6 million as at March 31, 2022.
  • About Badger Infrastructure Solutions Ltd.
    Badger Infrastructure Solutions Ltd. (TSX:BDGI) is North Americas largest provider of non-destructive excavating services.
  • The Badger Airvac complements the Badger Hydrovac, and both are designed and manufactured by Badger.
  • Badgers first quarter 2022 Managements Discussion and Analysis and 2022 Unaudited Interim Condensed Consolidated Financial Statements, along with all previous public filings of Badger Infrastructure Solutions Ltd. may be found on SEDAR at www.sedar.com.

RIT students, faculty, and alumni ready to descend on Manhattan for Design Week

Retrieved on: 
Thursday, May 12, 2022 - 10:30pm
Knowledge, Minneapolis College of Art and Design, University, Design Week, Education, Art, Vignelli Center for Design Studies, Engineering, Rochester Institute of Technology, Photography, International, Social media, International Contemporary Furniture Fair, Red Dot, Partner, Game Developers Choice Awards, ICFF, Castle, Massimo Vignelli, Health, School, COVID-19, RIT, Technology, Vaccination, Wendell Castle, Javits Center, Industry, Cat, Partnership, Student, Safety, Taste, Glass, Editing, Partners & Napier, Faculty, Design studies, Strate School of Design, Growth, Medicine, Nightclub, Fashion, Tutoring, Interior design, Management, Autodesk, Design, Bookend

ROCHESTER, N.Y., May 12, 2022 /PRNewswire-PRWeb/ -- After a three-year pause because of the pandemic, students, faculty, staff, and alumni from Rochester Institute of Technology's (RIT) College of Art and Design will descend on Manhattan this week for NYCxDesign—New York City's annual celebration of design that attracts hundreds of thousands from around the globe—which is marking its 10th year.

Key Points: 
  • "'RIT Success by Design' will celebrate the past, present, and future of design at RIT by highlighting its impact on the global design community through our remarkable alumni, current student successes, local and global assets, and future ambitions for growth," Owen said.
  • "It's great for RIT to be back at Design Week, and it is significant for the university to have such a formidable presence at one of the world's leading showcases for design."
  • RIT is among only a select few universities and design schools to be invited to Design Week in New York City.
  • For Metaproject 11, senior industrial design students spent last year designing products for Staach, which focuses on functional sustainable design.

Talaris Therapeutics Announces First Quarter Financial Results and Corporate Update

Retrieved on: 
Thursday, May 12, 2022 - 9:01pm
Degenerative disease, Risk, Company, Scleroderma, American Society of Transplantation, Private Securities Litigation Reform Act, Research, U.S. Securities and Exchange Commission, Â, HSCT, Nasdaq, Infection, 2021 Essex County Council election, Immune tolerance, Patient, ATC, COVID-19, Therapy, Clinical trial, Society, D, Adult, Vaccination, Kidney, IND, Genetic distance, Safety, Congress, Standard of care, Acute kidney injury, Security (finance), Hematopoietic stem cell transplantation, Growth, Immunosuppression, GLOBE, Pharmaceutical industry, Talari Networks

BOSTON and LOUISVILLE, Ky., May 12, 2022 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today reported financial results for the three-month period ended March 31, 2022, and provided an update on its business.

Key Points: 
  • It has been a productive start to the year, stated Scott Requadt, Chief Executive Officer of Talaris.
  • Alongside the meeting, we also plan to provide an interim update on our open-label FREEDOM-1 clinical study.
  • Talaris maintains corporate offices in Boston, MA, its cell processing facility in Louisville, KY, and additional research operations in Houston, TX.
  • Talaris explicitly disclaims any obligation to update any forward-looking statements.

New Contract Awarded by U.S. Department of Defense for the Procurement of up to Approximately $7.5 Million of Oral TPOXX®

Retrieved on: 
Thursday, May 12, 2022 - 9:05pm
Office of Inspector General, U.S. Department of Health and Human Services, Ix, Exercise, PEP, Smallpox, Monkeypox, Contract, Government, Human services, United States Department of Defense, EMA, Risk, Health Canada, Private Securities Litigation Reform Act, SIGA Technologies, Radiation, Documentation, Annual report, Policy, Xi, Cowpox, COVID-19, Vaccination, Research, Patent, GLOBE, U.S. Department of Defense Strategy for Operating in Cyberspace, Infection, Vaccine, IV, FDA, EAP, Biomedical Advanced Research and Development Authority, European Medicines Agency, Human, Phrase, Assistant, Vaccinia, Vii, NASDAQ, Authorization, Post-exposure prophylaxis, Forward-looking statement, Development, Project Bioshield Act, BARDA, CEO, Pharmaceutical industry

We continue to make progress in securing new customers for TPOXX, Phil Gomez, CEO of SIGA said.

Key Points: 
  • We continue to make progress in securing new customers for TPOXX, Phil Gomez, CEO of SIGA said.
  • We are pleased to be partnering with DoD to provide TPOXX to support the warfighter against smallpox as we continue development of the PEP indication.
  • On July 13, 2018, the FDA approved oral TPOXX for the treatment of smallpox to mitigate the impact of a potential outbreak or bioterror attack.
  • In December 2021, oral TPOXX was approved for the same indication by Health Canada.